4.6 Article

Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis

Journal

BJU INTERNATIONAL
Volume 113, Issue 2, Pages 228-235

Publisher

WILEY
DOI: 10.1111/bju.12242

Keywords

carcinoma; renal cell; diagnostics; prognosis

Funding

  1. Tampere University Hospital/Research Center/Elna Savolainen Fond

Ask authors/readers for more resources

Objective To evaluate imaging methods and prognoses between small renal cell carcinomas (RCCs) and larger tumours according to the era of diagnostics. Patients and Methods In all, 784 consecutive patients diagnosed with RCC between 1964 and 1997 at the Pirkanmaa Hospital District in Finland were included. Patients were divided into two groups: tumours of 3.0 and >3.0cm in diameter. Prognosis was analysed according to the era of diagnostics: (i) pre-computed tomography (CT) and pre-ultrasound (US), (ii) US era and (iii) CT era. Results Small tumours became more common: in the pre-CT and pre-US era, only 4.4% of tumours were small; however, in the CT era 16% were small tumours. More diagnostic methods were used in studying small tumours. CT proved to be the most reliable method, although it was actually better at diagnosing large tumours. Relapses occurred less frequently among patients with small tumours; more than half of the tumours that developed distant metastases (16.0%) already evinced them at the time of diagnosis. There were no relapses after 14 years of follow-up among small tumours, whereas large tumours relapsed within that time. RCC was the cause of death in 14.9% of patients with small tumours vs 50.7% with large tumours. The best prognosis was among patients with small tumours diagnosed with CT. Conclusion Among patients with small tumours, prognosis has improved along with better diagnostics, although some showed relapse during a surveillance period of up to 14 years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer

Juha P. Virman, Petri Bono, Tiina H. Luukkaala, Kaisa L. Sunela, Paula M. Kujala, Pirkko-Liisa I. Kellokumpu-Lehtinen

CLINICAL GENITOURINARY CANCER (2016)

Article Oncology

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhonen, T. Turpeenniemi-Hujanen, R. Asola, M. Leinonen, M. Hahka-Kemppinen, P. Kellokumpu-Lehtinen

ANNALS OF ONCOLOGY (2010)

Article Urology & Nephrology

Changes in symptoms of renal cell carcinoma over four decades

Kaisa L. Sunela, Matti J. Kataja, Pirkko-Liisa I. Kellokumpu-Lehtinen

BJU INTERNATIONAL (2010)

Article Oncology

A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

Kaisa Leea Sunela, Sanna Koskinen, Pirkko-Liisa Kellokumpu-Lehtinen

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)

Article Oncology

Influence of Body Mass Index and Smoking on the Long-Term Survival of Patients With Renal Cell Cancer

Kaisa Leea Sunela, Matti Jorma Kataja, Pirkko-Liisa Irmeli Kellokumpu-Lehtinen

CLINICAL GENITOURINARY CANCER (2013)

Article Oncology

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Aino Rajamaki, Kaisa Sunela, Roosa E. I. Prusila, Milla E. L. Kuusisto, Santiago Mercadal, Tuomas Selander, Hanne Kuitunen, Marjukka Pollari, Esa Jantunen, Ilja Nystrand, Juan-Manuel Sancho, Marc Sorigue, Outi Kuittinen

Summary: The role of sex in follicular lymphoma (FL) remains contradictory, with female patients showing better outcomes in terms of progression-free survival. However, sex does not significantly impact prognosis among patients with early progression of disease (POD). Male sex is identified as an adverse prognostic factor for FL, except in cases of early POD.

LEUKEMIA & LYMPHOMA (2021)

Article Urology & Nephrology

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

Sumanta K. Pal, Javier Puente, Daniel Y. C. Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A. Binder, Lixian Peng, Alan D. Smith, Sun Young Rha

Summary: In patients with advanced renal cell carcinoma, a lower starting dose of lenvatinib (14 mg) did not show comparable efficacy to the approved dose (18 mg), although safety results were similar.

EUROPEAN UROLOGY (2022)

Article Oncology

Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis

Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen

Summary: This study examined the proportion of deaths from progressive lymphoma and the impact of follicular lymphoma (FL) on survival. The results showed that deaths from progressive lymphoma are nearly as common as deaths from other causes in FL patients during the rituximab era. Despite improvements in survival, there was evidence of excess mortality resulting from FL for at least 10 years after diagnosis.

CANCER (2022)

Article Oncology

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

Cristiane Bergerot, Sun Young Rha, Sumanta Pal, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Jae Lyun Lee, Kaisa Sunela, Tudor Ciuleanu, Daniel Heng, Hilary Glen, Jinyi Wang, Lee Bennett, Janice Pan, Karen O'Hara, Javier Puente

Summary: This study focuses on preserving health-related quality of life during renal cell carcinoma treatment. The results showed that patients who received an 18 mg lenvatinib starting dose had better health-related quality of life scores and longer time to deterioration on most scales compared to those who received a 14 mg starting dose. These findings are important for guiding the treatment of renal cell carcinoma.

ONCOLOGIST (2023)

Article Oncology

FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Aino Rajamaki, Hanne Kuitunen, Marc Sorigue, Salla-Maarit Kokkonen, Outi Kuittinen, Kaisa Sunela

Summary: The clinical impact of FDG-PET/CT followed by a new biopsy based on maximum standardized uptake value was evaluated for detecting clinically unsuspected HT of FL. The study results suggest that rebiopsy based on high SUVmax is valuable in detecting clinically unsuspected FL HT.

CANCER MEDICINE (2023)

Letter Hematology

Link between disease status at 24 months and mortality in follicular lymphoma

Aino Rajamaki, Mika Hujo, Reijo Sund, Roosa E. I. Prusila, Milla E. L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Marc Sorigue, Juan-Manuel Sancho, Outi Kuittinen, Kaisa Sunela

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Review Oncology

Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment

I. Kaartinen, K. Sunela, J. Alanko, K. Hukkinen, M. -L. Karjalainen-Lindsberg, C. Svarvar

Article Oncology

VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer

Juha Virman, Petri Bono, Tiina Luukkaala, Kaisa Sunela, Paula Kujala, Pirkko-Liisa Kellokumpu-Lehtinen

ANTICANCER RESEARCH (2015)

Article Oncology

Claudins as Prognostic Factors for Renal Cell Cancer

Juha Virman, Ylermi Soini, Paula Kujala, Tiina Luukkaala, Tapio Salminen, Kaisa Sunela, Pirkko-Liisa Kellokumpu-Lehtinen

ANTICANCER RESEARCH (2014)

No Data Available